Infectious Disease Biopharmaceuticals

GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM)

Amesite

InMed Pharmaceuticals

Meiwu Tech

Co-Diagnostics

Phoenix Asia

Generation Income Properties

MetaVia

Rubico

Virax Biolabs

Agilysys

GOVX

IBBQ

SBIO

LABU

GeoVax Labs, Inc. emphasizes the critical need for scalable domestic vaccine manufacturing and diversified supply capabilities in light of escalating global infectious disease threats, including the Ebola outbreak and mpox developments. CEO David A. Dodd highlighted the importance of their GEO-MVA vaccine candidate, which is advancing towards a Phase 3 trial. The company aims to enhance biodefense preparedness and has received positive feedback from the European Medicines Agency for its regulatory pathway.

GeoVax Labs

iShares Biotechnology ETF

Invesco Nasdaq Biotechnology ETF

Proshares Ultra Nasdaq Biotech

ALPS Medical Breakthrough

First Trust NYSE Arca Biotech Index Fd

SPDR S&P Biotech

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

GeoVax Highlights Strategic Importance of Domestic MVA-Based Preparedness Infrastructure Amid Escalating Global Infectious Disease Threats

The Global Luminex Multiplex Assays Market is projected to grow from USD 1.82 billion in 2025 to USD 3.89 billion by 2033, at a CAGR of 10.0%. This growth is driven by the rising demand for high-throughput biomarker profiling and standardized testing workflows. Key factors include the efficiency of multiplex systems, regulatory support for standardized panels, and the expansion of outsourced research models. However, challenges such as validation complexity and elevated costs may impact adoption rates.

fidelity

Luminex Multiplex Assays Market Projected to Reach USD 3.89 Billion by 2033, Driven by Rising Demand for High-Throughput Biomarker Profiling and Standardized Multiplex Testing Workflows: Verified Market Research

GOVXW

GeoVax reported a Q1 2026 net loss of $5.3 million, with cash reserves of $1.3 million. Revenue from government contracts was $0, down from $1.6 million in Q1 2025 due to a contract termination. The company is advancing its GEO-MVA vaccine program and Gedeptin strategies in immuno-oncology. R&D expenses decreased to $3.9 million, while general and administrative expenses fell to $1.4 million. The company plans to initiate a Phase 3 trial for GEO-MVA and continues to focus on Gedeptin's development.

TradingView

Invesco Biotechnology & Genome ETF

GeoVax Reports Q1 2026 Net Loss $5.3M, Cash $1.3M, Advances GEO-MVA Phase 3 Plans

GeoVax Labs reported $2.489 million in revenue for the year, with a net loss of $(21.465) million, an improvement from the previous year. The operating loss was $(21.639) million, attributed to reduced R&D spending. The company is advancing its GEO-MVA program toward Phase 3 and has multiple Phase 2 trials for GEO-CM04S1. The Gedeptin cancer program has completed Phase 1/2 trials. GeoVax has raised capital through equity tranches to support its initiatives, with a cash runway extending into mid-Q2 2026.

GeoVax Labs 10-K: Revenue $2.489M, Net Loss $(21.465) M

GeoVax Labs has raised approximately $863,000 through a warrant exercise inducement, allowing existing warrant holders to exercise 634,658 warrants at a reduced price of $1.36 per share. In return, the company will issue new warrants for up to 1,269,316 shares at the same price, valid for five years pending Nasdaq approval. A.G.P./Alliance Global Partners served as the exclusive financial advisor for this transaction, receiving a 7% fee and up to $40,000 in legal expenses.

GeoVax Labs Raises $863K Via Warrant Exercise Inducement; Issues New 5-Year Warrants at $1.36

Earnings Watch

GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM) | 10-Q: FY2025 Q2 Revenue: USD 2.489 M

GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM) | 8-K: FY2025 Q1 Revenue: USD 1.637 M

GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM) | 10-Q: FY2025 Q1 Revenue: USD 1.637 M

GEOVAX LABS INC C/WTS 29/09/2025(TO PUR COM)(GOVXW.US)